4 completed, 1 recruiting, 1 terminated. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Recruiting 1, Terminated 1 |
Follow C3 Glomerulonephritis: new trials by email Literature Review of C3 Glomerulonephritis trials Research Report on C3 Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Pegcetacoplan - C3G, IC-MPGN | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2021-09-07 | 2026-04-21 |
| Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Aliskiren, Enalapril - C3 Glomerulopathy, Membranoproliferative Glomerulonephritis | Phase 2 | Recruiting | Region Skane | 30 | 2020-10-01 | 2025-06-22 |
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 22 | 2018-06-20 | 2023-08-21 |
| A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) Danicopan, Placebo - C3 Glomerulopathy, C3 Glomerulonephritis | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2018-06-12 | 2022-10-14 |
| Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies APL-2 - IgA Nephropathy, Lupus Nephritis | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 21 | 2018-02-26 | 2025-02-13 |
| A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN Danicopan - C3 Glomerulonephritis, Dense Deposit Disease | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 6 | 2017-08-09 | 2021-11-04 |
Glomerulonephritis, Membranoproliferative (6) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranous (1) · Lupus Nephritis (1)
Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Glomerulonephritis (6) · Immune System Diseases (6) · Kidney Diseases (6) · Male Urogenital Diseases (6) · Nephritis (6) · Urogenital Diseases (6) · Urologic Diseases (6) · Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Lupus Erythematosus, Systemic (1) · Skin and Connective Tissue Diseases (1)
danicopan (3) · Enalapril (1) · aliskiren (1) · pegcetacoplan (1) · rhoA GTP-Binding Protein (1)
Alexion Pharmaceuticals, Inc. (3) · Apellis Pharmaceuticals, Inc. (2) · Region Skane (1)
United States (4) · Australia (3) · Netherlands (3) · Belgium (2) · Italy (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Brazil (1) · France (1) · Spain (1) · Sweden (1) · Switzerland (1)
Diana Karpman (1)
2017 (2), 2016 (1), 2019 (1)